Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPONTE NETO, Alberto Machado da
dc.contributor.authorCLEMENTE, Aniele Cristine Ott
dc.contributor.authorROSA, Paula Waki
dc.contributor.authorRIBEIRO, Igor Braga
dc.contributor.authorFUNARI, Mateus Pereira
dc.contributor.authorNUNES, Gabriel Cairo
dc.contributor.authorMOREIRA, Luana
dc.contributor.authorSPARVOLI, Luiz Gustavo
dc.contributor.authorCORTEZ, Ramon
dc.contributor.authorTADDEI, Carla Romano
dc.contributor.authorMANCINI, Marcio C.
dc.contributor.authorMOURA, Eduardo Guimaraes Hourneaux de
dc.date.accessioned2023-10-30T14:56:26Z
dc.date.available2023-10-30T14:56:26Z
dc.date.issued2023
dc.description.abstractBACKGROUNDMetabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.AIMTo evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.METHODSThis was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.RESULTSThere was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.CONCLUSIONThere were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.identifier.citationWORLD JOURNAL OF CLINICAL CASES, v.11, n.19, p.4612-4624, 2023
dc.identifier.doi10.12998/wjcc.v11.i19.4612
dc.identifier.issn2307-8960
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/56323
dc.language.isoeng
dc.publisherBAISHIDENG PUBLISHING GROUP INCeng
dc.relation.ispartofWorld Journal of Clinical Cases
dc.rightsopenAccesseng
dc.rights.holderCopyright BAISHIDENG PUBLISHING GROUP INCeng
dc.subjectFecal microbiota transplantationeng
dc.subjectMetabolic syndromeeng
dc.subjectObesityeng
dc.subjectEndoscopyeng
dc.subjectDiabetes mellituseng
dc.subjectEndocrinologyeng
dc.subject.otherclostridium-difficile infectioneng
dc.subject.otherintestinal microbiotaeng
dc.subject.otherinsulin sensitivityeng
dc.subject.othergut microbiomeeng
dc.subject.othermetformineng
dc.subject.otheradultseng
dc.subject.wosMedicine, General & Internaleng
dc.titleFecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trialeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalCLEMENTE, Aniele Cristine Ott:Univ Sao Paulo, Hosp Clin, Dept Endocrinol, Sch Med, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.author.externalNUNES, Gabriel Cairo:Univ Sao Paulo, Serv Endoscopia Gastrointestinal, Fac Med, Dept Gastroenterol,Hosp Clin, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.author.externalMOREIRA, Luana:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.author.externalSPARVOLI, Luiz Gustavo:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.author.externalCORTEZ, Ramon:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.author.externalTADDEI, Carla Romano:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05403010 Sao Paulo, SP, Brazil; Univ Sao Paulo, Sch Arts Sci & Humanities, BR-05403010 Sao Paulo, SP, Brazil
hcfmusp.contributor.author-fmusphcALBERTO MACHADO DA PONTE NETO
hcfmusp.contributor.author-fmusphcPAULA WAKI LOPES DA ROSA
hcfmusp.contributor.author-fmusphcIGOR BRAGA RIBEIRO
hcfmusp.contributor.author-fmusphcMATEUS PEREIRA FUNARI
hcfmusp.contributor.author-fmusphcMARCIO CORREA MANCINI
hcfmusp.contributor.author-fmusphcEDUARDO GUIMARAES HOURNEAUX DE MOURA
hcfmusp.description.beginpage4612
hcfmusp.description.endpage4624
hcfmusp.description.issue19
hcfmusp.description.volume11
hcfmusp.origemWOS
hcfmusp.origem.pubmed37469721
hcfmusp.origem.wosWOS:001032687700012
hcfmusp.publisher.cityPLEASANTONeng
hcfmusp.publisher.countryUNITED STATESeng
hcfmusp.relation.referenceAlberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.xeng
hcfmusp.relation.referenceAllegretti JR, 2020, CLIN GASTROENTEROL H, V18, P855, DOI 10.1016/j.cgh.2019.07.006eng
hcfmusp.relation.referenceBäckhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101eng
hcfmusp.relation.referenceBagdasarian N, 2015, JAMA-J AM MED ASSOC, V313, P398, DOI 10.1001/jama.2014.17103eng
hcfmusp.relation.referenceCammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046eng
hcfmusp.relation.referenceCHAO A, 1984, SCAND J STAT, V11, P265eng
hcfmusp.relation.referenceChu ND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170922eng
hcfmusp.relation.referenceClarke JTR, 2005, METABOLIC SYNDROME T, P28eng
hcfmusp.relation.referenceCostello SP, 2017, ALIMENT PHARM THER, V46, P213, DOI 10.1111/apt.14173eng
hcfmusp.relation.referenceDao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778eng
hcfmusp.relation.referenceDavidovics ZH, 2019, J PEDIATR GASTR NUTR, V68, P130, DOI 10.1097/MPG.0000000000002205eng
hcfmusp.relation.referenceDruart C, 2014, LIPIDS, V49, P397, DOI 10.1007/s11745-014-3881-zeng
hcfmusp.relation.referenceEckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7eng
hcfmusp.relation.referenceEdgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381eng
hcfmusp.relation.referenceForslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766eng
hcfmusp.relation.referenceGBD 2015 Obesity Collaborators, 2017, N Engl J Med, V377, P13, DOI 10.1056/NEJMoa1614362eng
hcfmusp.relation.referenceGrundy SM, 2007, J CLIN ENDOCR METAB, V92, P399, DOI 10.1210/jc.2006-0513eng
hcfmusp.relation.referenceKittelson JM, 2011, J BIOPHARM STAT, V859eng
hcfmusp.relation.referenceKootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008eng
hcfmusp.relation.referenceKozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13eng
hcfmusp.relation.referenceLe Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506eng
hcfmusp.relation.referenceLey RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102eng
hcfmusp.relation.referenceLindsay Robert S, 2004, Curr Diab Rep, V4, P63, DOI 10.1007/s11892-004-0013-9eng
hcfmusp.relation.referenceLozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005eng
hcfmusp.relation.referenceLozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550eng
hcfmusp.relation.referenceNavas-Molina JA, 2013, METHOD ENZYMOL, V531, P371, DOI 10.1016/B978-0-12-407863-5.00019-8eng
hcfmusp.relation.referenceNishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5eng
hcfmusp.relation.referencePlovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236eng
hcfmusp.relation.referenceProença IM, 2020, NUTR RES, V83, P1, DOI 10.1016/j.nutres.2020.06.018eng
hcfmusp.relation.referencePylro VS, 2014, J MICROBIOL METH, V107, P30, DOI 10.1016/j.mimet.2014.08.018eng
hcfmusp.relation.referenceQuast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219eng
hcfmusp.relation.referenceReaven G M, 1997, Nutrition, V13, P66eng
hcfmusp.relation.referenceReunanen J, 2015, APPL ENVIRON MICROB, V81, P3655, DOI 10.1128/AEM.04050-14eng
hcfmusp.relation.referenceSaklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-zeng
hcfmusp.relation.referenceSasson AN, 2021, LANCET GASTROENTEROL, V6, P754, DOI 10.1016/S2468-1253(21)00097-2eng
hcfmusp.relation.referenceShah AY, 2020, AM J GASTROENTEROL, V115, P814, DOI 10.14309/ajg.0000000000000604eng
hcfmusp.relation.referenceSHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.xeng
hcfmusp.relation.referenceShen NT, 2017, GASTROENTEROLOGY, V152, P1889, DOI 10.1053/j.gastro.2017.02.003eng
hcfmusp.relation.referenceShin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839eng
hcfmusp.relation.referenceSmits LP, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008342eng
hcfmusp.relation.referenceStrauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845eng
hcfmusp.relation.referenceVallianou NG, 2019, HORM-INT J ENDOCRINO, V18, P141, DOI 10.1007/s42000-019-00093-weng
hcfmusp.relation.referencevan Nood E, 2013, NEW ENGL J MED, V368, P407, DOI [10.1056/NEJMoa1205037, 10.1056/NEJMc1303919]eng
hcfmusp.relation.referenceVrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031eng
hcfmusp.relation.referenceZhang Q, 2020, DIABET METAB SYND OB, V13, P5003, DOI 10.2147/DMSO.S286430eng
hcfmusp.relation.referenceZhang ZX, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102291eng
relation.isAuthorOfPublicationaa9a15ab-1217-491e-86a1-c308c803f231
relation.isAuthorOfPublication0f9d82d4-61a9-44b7-8d8a-f100aca00730
relation.isAuthorOfPublication938f5746-02bd-4e1f-9788-086fe7962335
relation.isAuthorOfPublicationa528753d-2a18-49dc-b6cf-756dca1aeaeb
relation.isAuthorOfPublication69ff635e-8f5c-467d-a49a-a55e108e4d3d
relation.isAuthorOfPublication517f6297-b2fc-4922-8fa3-ccc23ee287c7
relation.isAuthorOfPublication.latestForDiscoveryaa9a15ab-1217-491e-86a1-c308c803f231
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_PONTE NETO_Fecal_microbiota_transplantation_in_patients_with_metabolic_syndrome_2023.PDF
Tamanho:
1.44 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - LIM/35